Nuvectis Pharma
NVCT
11 hedge funds and large institutions have $7.2M invested in Nuvectis Pharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
55% more capital invested
Capital invested by funds: $4.65M → $7.2M (+$2.55M)
38% more funds holding
Funds holding: 8 → 11 (+3)
0.12% more ownership
Funds ownership: 4.94% → 5.06% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$1.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$434K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$288K |
| 4 |
State Street
Boston,
Massachusetts
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Ronit Capital
London,
United Kingdom
|
-$1.62M |
| 2 |
Millennium Management
New York
|
-$312K |
| 3 |
VF
Virtu Financial
New York
|
-$84K |
| 4 |
BlackRock
New York
|
-$8.33K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RC
1
Ronit Capital
London,
United Kingdom
| $4.7M | -$1.62M | -130,718 | -24% |
|
|
BWP
2
Baldwin Wealth Partners
Marion,
Massachusetts
| $1.35M | +$1.5M | +121,000 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $393K | +$434K | +35,069 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $268K | +$113K | +9,145 | +62% |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $261K | +$288K | +23,257 | New |
|
|
6
State Street
Boston,
Massachusetts
| $131K | +$145K | +11,700 | New |
|
|
7
BlackRock
New York
| $80K | -$8.33K | -674 | -9% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $14K | -$5.82K | -471 | -27% |
|
9
Morgan Stanley
New York
| $2K | +$2.47K | +200 | New |
|
10
UBS Group
Zurich,
Switzerland
| $1K | -$977 | -79 | -56% |
|
|
11
Millennium Management
New York
| – | -$312K | -42,160 | Closed |
|
|
VF
12
Virtu Financial
New York
| – | -$84K | -11,365 | Closed |
|
13
Wells Fargo
San Francisco,
California
| – | +$12 | +1 | +5% |
|
NVCT Hedge Fund Activity: Q2 2022 in Review
11 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2022, worth a combined $7.2M — up 55% from $4.65M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NVCT positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Baldwin Wealth Partners, opening a new position worth an estimated $1.5M. The largest seller was Ronit Capital, cutting an estimated $1.62M.
- 11 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2022, up from 8 in Q1 2022.
- Funds reported $7.2M of Nuvectis Pharma stock for Q2 2022, up 55% quarter-over-quarter.
- 5 funds opened new Nuvectis Pharma positions in Q2 2022 and 2 closed out, a net change of +3 holders.
- The largest Nuvectis Pharma buyer in Q2 2022 was Baldwin Wealth Partners, an estimated $1.5M added.
- The largest Nuvectis Pharma seller in Q2 2022 was Ronit Capital, an estimated $1.62M sold.
Based on aggregated 13F filings for Q2 2022.